A possible mechanism of action for this molecule may be inferred from the findings of a recent study reporting that the expression of RANTES by breast tumor cells results not only in monocyte migration to the tumor site but also in pro-tumorigenic activities of RANTES, that may contribute to disease progression. This evidence concerns the gene CCL5 and breast neoplasm.